NEW YORK – Cambridge, Massachusetts-based Repertoire Immune Medicines on Monday said the first patient with human papillomavirus-16-positive advanced cancer has received its investigational T-cell therapy RPTR-168 in a Phase I trial.
The company's autologous T-cell therapy includes the immunomodulatory agent IL-12 and is designed to target five antigens involved in the development of HPV-16-positive tumors. The company collects T cells from each patient, primes and expands the cells with the five antigens, and then delivers them back into the patient with IL-12, which can promote T-cell function and improve the treatment's anti-tumor activity. Repertoire has also tried to address the dose-related toxicities known to occur with IL-12 by attaching it to the surface of multi-targeted T cells using a proprietary tethering technology.
In the Phase I open-label, multicenter trial of RPTR-168, Repertoire will explore the treatment's safety and tolerability in patients with relapsed or refractory, metastatic or locally advanced HPV-16-positive tumors. Multiple cancer centers in the US are serving as trial sites; the first patient to receive treatment in the study was enrolled at the HonorHealth Research and Innovation Institute in Scottsdale, Arizona.
"The ability to safely deliver IL-12 with a multi-targeted cell therapy would be a significant advancement in the treatment of solid tumors," Ted Reiss, chief medical officer at Repertoire, said in a statement. "We believe the use of cell-tethered IL-12 has the potential to enhance T-cell responses in the microenvironment of solid tumors."